Tidepath

Peptide library

Growth-hormone peptides

One hormone, two receptor pathways, and evidence ranging from an FDA label to very little.

Several signals control how much growth hormone the body releases. One of them, somatostatin, holds it back. The peptides here work through two of those signals. Sermorelin, the two forms of CJC-1295 and tesamorelin copy the brain hormone that tells the pituitary gland to release growth hormone. That hormone is GHRH, so these are called GHRH analogues. Ipamorelin reaches the same gland through a different receptor, the one the hormone ghrelin uses.

They differ in which receptor they work through, and in the evidence behind them. Tesamorelin has an FDA label and a half-life (the time it takes for half a dose to clear) measured in people. Sermorelin used to be FDA-approved and isn't any more. CJC-1295 with DAC (an add-on that keeps it in the blood for days) has published human studies of how long it lasts and how the body clears it (pharmacokinetics). We found none for the form without DAC. Ipamorelin isn't FDA-approved. Its half-life has been measured in people given it into a vein, but none of our sources measures it injected under the skin. Five peptides, two receptors, and evidence ranging from an FDA label to very little.

In this group

Why the variants matter

Two names in this group can each mean two different drugs. "CJC-1295" on its own could mean the DAC form, which lasts for days in the body, or the form without DAC. "GRF 1-29" could mean sermorelin or the modified version, Mod GRF 1-29, which are different molecules. Tidepath asks which one you mean every time instead of guessing.

What we don't cover

These pages say where each dose comes from, or that there's no checked dose range, and how long each lasts where that's known. The ipamorelin and CJC-1295 pages also give the FDA's safety notes, including serious health problems reported when ipamorelin was given into a vein. Otherwise they don't cover side effects, who shouldn't take them (contraindications), what to monitor, or drug interactions.

Get an early invite to Tidepath

The app isn't in the App Store yet. Leave your email for an early invite, and tips for your first month.

Get an early invite, tips and occasional news from Tidepath. Unsubscribe anytime. Privacy · Health data privacy · Sender and contact details